Reduction of @entity1 @entity320 growth in XXXX @entity19 by passive transfer of antibodies induced by a high molecular weight @entity320 -associated antigen mimotope vaccine.

@entity1 @entity5 @entity19 @entity320 @entity466
PURPOSE: The high molecular weight @entity320 -associated antigen (HMW-MAA) is an attractive target for immunotherapy of @entity320 . We have recently generated a vaccine based on the HMW-MAA mimotope 225D9.2+ that was able to induce anti-HMW-MAA antibodies with antitumor activity in vitro. Here, we investigated the antitumor activity of these antibodies in a @entity1 @entity320 xenotransplant @entity466 ( @entity466 ) @entity19 model. EXPERIMENTAL DESIGN: @entity5 were established by injecting the @entity1 @entity320 518A2 cells into C.B.17 @entity466 / @entity466 @entity19 . In @entity5 prevention experiments, 200 microg purified total IgG antibodies were injected intravenously the same day or on day 5 in therapeutic experiments. Antibody administration was repeated every fourth day and @entity5 volumes were measured. Antibody specificity and @entity5 infiltration by macrophages were investigated by immunohistochemistry. RESULTS: Within 35 days after cell inoculation, antibody treatment reduced @entity5 growth up to 40% in the therapeutic and up to 62% in the @entity5 prevention experiments compared with the control @entity19 . In @entity5 of all groups, a similar distribution of the HMW-MAA and no differences in infiltration of macrophages were detected by immunohistochemistry. CONCLUSIONS: Here, we showed that antibodies induced by the 225D9.2+ mimotope effectively inhibited @entity320 growth. Additional mechanisms besides antibody-dependent cell cytotoxicity like disruption of interactions of @entity320 cells mediated by extracellular matrix components seem to be involved in @entity5 growth inhibition. Based on our findings, we suggest that active immunization with this mimotope might be a promising strategy for treatment of @entity320 .
